Navigation Links
Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth
Date:4/20/2009

sented an update on its cell proliferation technology at the AACR Conference.

Progen's lead cell proliferation product, PG11047, targets hyper-proliferating cells specifically to inhibit tumor growth, and is currently undergoing two phase 1 clinical trials.

The pre-clinical research presented at the Conference showed the product provides a significant additive anti-cancer effect when combined with Cisplatin and Avastin when compared with either drug alone in lung cancer and prostate cancer models respectively.

Progen is currently progressing PG11047 through early clinical development in parallel to additional translational studies to determine the most promising indications.

Mr Homburg said to date, 44 patients had been treated in the monotherapy PG11047 Phase 1 trial, and over 130 patients in combination studies with approved anti-cancer therapies. The dosing regime in the monotherapy trial has been escalated far beyond Progen's original expectations.

"While we expect to find the maximum dose soon, we already have supporting data that the drug will have a large therapeutic window when given as a monotherapy," he said.

Mr Homburg said the latest findings in Progen's epigenetics and cell proliferation technologies represented another important milestone in the development of its anti-cancer portfolio.

"These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline," he said.

"We have a fantastic team of collaborators, who have played a significant role in these achievements.

"We are very pleased to have had the opportunity to present these findings on the world stage, among leaders of the international scientific community."

About Progen

Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, developme
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
2. ProGenTech Limited Appoints Executive Management Team
3. ProGenTech Completes $21 Million Series C Financing
4. Radioactive progenies of thoron can be measured accurately, thanks to the PTB
5. Neural progenitor cells as reservoirs for HIV in the brain
6. Progen Investor Teleconference Dial In Details
7. Elusive pancreatic progenitor cells found in mice
8. Imaging neural progenitor cells in the living human brain
9. Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
10. Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... New York, NY (PRWEB) December 22, 2014 ... a noticeable toll and can present in the form ... nasolabail folds with the start of the marionette line ... peels, topical treatments and diligent skincare, but as the ... Radiesse, and Restylane are all synthetic fillers that can ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The holidays are ... of the season. Many may be thinking about how to ... of a few weeks. Health Republic Insurance of New York ... Dietitian, Andrea Chernus, to provide some smart ideas to enjoy ... healthy. , 1)    Avoid arriving at a holiday gathering over-hungry , ...
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Super Saturday, ... Friday this year as the busiest day in the ... retailers, The Grass Station had a steady pre-Christmas stream ... gifts, this past Saturday. , “I definitely intend to ... Robert, a Denver resident who was enjoying The Grass ...
Breaking Medicine News(10 mins):Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2
... syndrome, the most commonly identified cause of cognitive impairment, ... Additionally, nearly 80 percent of fetuses with Down syndrome ... Control (CDC), in partnership with the National Down Syndrome ... current knowledge of Down syndrome, identify information gaps and ...
... researchers at George Mason University, INOVA Fairfax Hospital and ... new therapies for combating chronic diseases associated with obesity, ... American adults in 2005-06 according to the Centers for ... from morbidly obese patients undergoing weight loss surgery, the ...
... Medical,Corporation (Nasdaq: ROCM ) today announced operating results ... The Company reported record sales of $9,512,000 for ... of last year. The Company,also reported quarterly net income ... or $.06 per diluted share for the fourth quarter ...
... Profit Margin ... improves to 76%, CLEVELAND, Nov. 6 ... focused on global,eClinical solutions for the clinical trials industry, today reported its,operating ... For the three months ended September 30, 2008, revenue increased 12%,compared to ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
... a workplace chemical are often to blame, experts say ... variety of substances can cause the skin condition known ... with proper diagnosis and treatment, experts say. , Contact ... skin resulting from contact with a chemical, biologic or ...
Cached Medicine News:Health News:Melanin production discovered in fat tissue 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 8Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 9Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7Health News:Dermatitis Can Have Many Causes 2
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah ... brief providing a summary of the 2015 marketplace ... enrollment trends.  According to a ... Planning and Evaluation, Department of Health and Human ... enrolled in individual medical plans through the Marketplace ...
(Date:12/22/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the IND ... and is now open and that this program has ... and Human Services (HHS), through the Biomedical Advanced Research ... pleased to have the IND now active for our ... in our company,s partnership with BARDA as we continue ...
(Date:12/22/2014)... , Dec. 22, 2014 TWi Biotechnology, ... of Allowance for AC-201, TWi Biotechnology,s lead drug ... China for patent application ... pharmaceutically acceptable salts, active metabolite for treatment of ... methods of treatment using AC-201 for type II ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... DOTmed, the leading public medical equipment marketplace, and the ... have been selected by the Mid-Atlantic Group Network of Shared ... used medical equipment and idle assets. MAGNET was created ... in the niche market of capital equipment. , Derwood B. ...
... Nov. 5 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Trademark Office has issued a patent covering the approved ... treatment of phenylketonuria (PKU). The patent expires in ... based on the discovery that food increases the bioavailability ...
Cached Medicine Technology:MAGNET Selects DOTmed.com to Assist Members in Sale of Used Medical Equipment and Idle Assets 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 3United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 4
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... QuickVue+ Infectious Mononucleosis test is ... antibodies in serum, plasma or whole ... utilizes an extract of bovine erythrocytes ... specificity than similar extracts prepared from ...
... the first available point-of-care diagnostic test that ... of influenza A and B. The test ... an enzyme that assists viral replication by ... infected cells. The ZstatFlu substrate is labeled ...
Medicine Products: